Myomectomy Market research report by type (abdominal, hysteroscopic, laparoscopic, robotic), product (laparoscopic power morcellators, harmonic scalpel, laparoscopic sealers), end user (hospitals, surgical centers, medical device companies) - forecast till 2032

Global Myomectomy Market Overview

Myomectomy Market Size was valued at USD 1.2 Billion in 2023. The Global Myomectomy industry is projected to grow from USD 1.5 Billion in 2024 to USD 3.4 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.56% during the forecast period (2024 - 2032).Myomectomy a surgical procedure for the removal uterine fibroids. Uterine fibroids are common noncancerous growth in the uterus of women at their child bearing age, causing symptoms such as heavy bleeding during menstrual cycle, increased menstrual cramping, pain in pelvis or lower back, and swelling enlargement of the abdomen. 

Myomectomy differs from hysterectomy. During myomectomy, the surgeons remove only the fibroids in the uterus while in hysterectomy entire uterus is removed. This procedure preserves the chances of women getting pregnant. There are four types of myomectomy namely; abdominal, hysteroscopic, laparoscopic, and robotic. Results of myomectomy are found to be better and women report improvement in fibroid symptoms, such as heavy menstrual bleeding and pelvic pressure.

Rising prevalence of uterine fibroids, and increasing demand for diagnosis and treatment of uterine disorder. Additionally, increasing demand for medical devices for gynecology procedures also fuel the growth of the myomectomy market. Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influence the myomectomy market growth. Splendid research in the field of reproductive health and diseases also boost the myomectomy market.

The growth of medical device industry and increasing demand for technological advanced medical devices also fuels the growth of the myomectomy market across the globe. However, the growth of the myomectomy market is restricted due to increasing competition among existing players and high cost of medical devices.

According to the U.S. Department of Health and Human Services office on Women Health, about 20% to 80% of women develop fibroids by the age of 50 and nearly 30% will get them at the age of 35. Uterine fibroids are most common in women in their 40s and early 50s. Not all women with fibroids have symptoms; nearly 45% to 50% of the women do not exhibit symptoms in their lifespan. Increase in the age also affect the prevalence rate of uterine fibroids.

Olympus announced the U.S. market launch of its Moresolution power morcellator in November 2022. The company stated that it endorses the safe use of gynecologic devices under FDA guidance. The FDA issued definitive guidance on power morcellators in 2020 in response to concerns regarding the potential for cancer to spread. The agency advised restricting the use of laparoscopic power morcellation (LPM) to specific tissue containment systems. The procedure was also exclusively recommended for premenopausal women under the age of 50 who have suspected fibroid tumors. Olympus regards the PneumoLiner as a groundbreaking containment device, and Moresolution functions in tandem with it. According to the organization, the Olympus Contained Tissue Extraction System offers a laparoscopic surgical alternative to a limited number of patients. Consequently, it serves as an alternative to an open hysterectomy or open myomectomy in terms of tissue excision. According to Olympus, Moresolution is capable of removing dense or calcified fibroids. Furthermore, its precise cutting capabilities may contribute to the reduction of operating room time. There are safety features, such as a "cut" or "no cut" mode, a lightweight handpiece, and autoclavable and reusable components.

Myfembree was recently approved by the Food and Drug Administration (FDA) as the first once-daily treatment for excessive menstrual bleeding that is linked to uterine fibroids in June 2021. Symptoms are not always present with uterine fibroids. The quality of life of an individual can be significantly impacted by the excessive bleeding and pelvic pain that they can induce when they occur. Myfembree has the potential to transform the lives of individuals who have previously only had limited and invasive treatment options, according to experts. Myfembree is a pill that contains a gonadotropin-releasing hormone antagonist (relugolix), estradiol (E2), and norethindrone acetate (NETA). These ingredients collaborate to alleviate excessive menstrual bleeding. Myovant Sciences evaluated the response rate of the women who participated in their studies on the efficacy of Myfembree. The response was defined as a 50% reduction in menstrual blood loss volume during the last 35 days of treatment and a menstrual blood loss volume of fewer than 80 milliliters. In the studies, Myfembree exhibited response rates of 72.1% and 71.2% in menstrual blood loss at the 24-week mark, respectively, in contrast to 16.8% and 14.7% of women in the placebo group. Pfizer. Pfizer and Myovant Sciences have received FDA approval for Myfembree, the first once-daily treatment for excessive menstrual bleeding associated with uterine fibroids. The menstrual blood loss of the women who received Myfembree was reduced by 82% and 84.3%.

In November 2023, Gynesonics introduced an FDA-approved diagnostic intrauterine imaging device and transcervical treatment for symptomatic uterine fibroids. It is able to treat up to 80% of adult females who have developed this condition through the use of the novel technology.

For instance, in November 2022, Olympus indicated that it had launched the moresolution Power Morcellator produced by TROKAMED GmbH and distributed across the United States via a distribution agreement with Olympus America Inc. According to a press release, these products are designed specifically for advanced gynecologic procedures and can handle large calcified tissue samples. The Pneumoliner from Olympus and the more solution Morcellator may offer some patients laparoscopic surgery options.

In April 2022, Ethicon (a division of Johnson & Johnson MedTech) released its revolutionary ENSEAL X1 Straight Jaw Tissue Sealer. This device is positioned as an open or laparoscopic general, gynecological or urologic procedure tool.

Hologic Inc., a global leader in women’s health, announced in August 2021 that Anthem Blue Cross Blue Shield has modified its medical policy to include coverage of RF ablation (LAP-RFA) on women suffering from uterine fibroids including Acessa procedure (CPT Code 58674).

Gynesonics revealed in October 2021 that Texas’ first doctor in Austin would be administering Sonata treatment as an office-based procedure for uterine fibroid patients at his River Place OB/GYN facility – Dr. John Thoppil.

Myomectomy Market Segment Insights  

The myomectomy market is segmented on the basis of type, product, and end user.

Myomectomy Type Insights

On the basis of type, myomectomy market is segmented into abdominal, hysteroscopic, laparoscopic, and robotic.

Myomectomy Product Insights

On the basis of product, the myomectomy market is segmented into laparoscopic power morcellators, harmonic scalpel, laparoscopic sealer, and others.

Myomectomy End-User Insights

On the basis of end user, the myomectomy market is segmented into hospitals & clinics, surgical centers, medical device companies, and others.

Myomectomy Regional Insights

America holds the first position in the myomectomy market owing to the rising prevalence of uterine disorders in the U.S., and increasing demand for new diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in healthcare IT industry.  Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.

Europe is the second largest market for myomectomy. In Europe, there is an increasing demand for medical devices and availability of funds for research and development activities in the reproductive health. The growth of surgical devices in Germany, France, and U.K also fuels the growth of the market.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing women suffering from uterine disorders, and rising investment in surgical device industry by key players in developing economies throughout Asia Pacific. India, China, and Japan are major contributors to the growth of the myomectomy market. This growth is attributed to an increasing demand technologically advanced medical devices such as gene chips for research activities, and availability of highly qualified medical professional such as surgeons and gynecologists.

The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about diagnosis and treatment of uterine fibroids. In the Middle East & Africa, Middle East captures the largest market share for myomectomy owing to the availability of better healthcare infrastructure, availability of specialty services and wide scope for research. 

Key Players in the Myomectomy Market    

Some of the key players in myomectomy market are

• Halt Medical, Inc. (U.K)


• Boston Scientific Corporation (U.S.)


• CooperSurgical Inc. (U.S.)


• C. R. Bard, Inc. (U.S.)


• F. Hoffmann-La Roche Ltd (Switzerland)


• General Electric Company (U.S.),


• KARL STORZ SE & Co. KG (Germany)


• Richard Wolf Medical Instruments (U.S.)


• Siemens (U.S.)


• AbbVie Inc. (U.S.)


• Bayer (Germany)


• Eli Lilly and Company (U.S.)


• Johnson & Johnson Services Inc. (U.S.)

Intended Audience

• Medical Device Manufacturers


• Medical Device Suppliers


• Medical Research Laboratories


• Healthcare IT Companies


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors